Sarepta Therapeutics Quarterly Balance Sheet
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Sarepta Therapeutics financial position
As of Jun 30, 2026, Sarepta Therapeutics reported total assets of $3.19 billion, down 13.4% from a year earlier against total liabilities of $1.66 billion. Shareholders' equity stood at $1.53 billion, or 47.9% of assets. The company held $571.1 million in cash and equivalents against $847.6 million of debt, a net debt position of $276.5 million.
The current ratio (current assets divided by current liabilities) was 4.42, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.55.
Summary generated from market data by MetaCap's automated system. Methodology
Sarepta Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 571.15M | 464.45M | 801.28M | 613.08M | 510.60M | 240.87M | 1.10B | 197.85M | 383.62M | 427.29M | 428.43M | 541.93M |
| Short-Term Investments | 217.34M | 188.74M | 138.37M | 237.92M | 289.54M | 281.89M | 251.78M | 1.00B | 1.08B | 963.45M | 1.25B | 1.19B |
| Receivables | 376.82M | 394.82M | 398.23M | 395.74M | 527.29M | 659.37M | 601.99M | 434.52M | 360.00M | 378.81M | 400.33M | 318.86M |
| Inventory | 904.27M | 1.00B | 914.74M | 1.08B | 994.04M | 941.43M | 749.96M | 565.92M | 485.80M | 373.53M | 322.86M | 244.01M |
| Total Current Assets | 2.22B | 2.31B | 2.54B | 2.72B | 2.66B | 2.43B | 3.07B | 2.69B | 2.68B | 2.46B | 2.58B | 2.45B |
| Property, Plant & Equipment | 325.99M | 336.24M | 345.13M | 358.94M | 371.86M | 360.59M | 340.34M | 305.79M | 276.20M | 249.30M | 227.15M | 212.37M |
| Intangible Assets | 30.61M | 31.38M | 28.95M | 29.68M | 30.52M | 26.20M | 26.89M | 27.57M | 28.25M | 28.93M | 29.62M | 19.50M |
| Long-Term Investments | 145.37M | 81.94M | 1.05M | 1.04M | 34.60M | 109.13M | 133.16M | 181.77M | — | 33.90M | 0 | — |
| Total Assets | 3.19B | 3.18B | 3.35B | 3.49B | 3.68B | 3.47B | 3.96B | 3.60B | 3.42B | 3.22B | 3.26B | 3.11B |
| Accounts Payable | 50.98M | 70.38M | 280.84M | 94.02M | 136.70M | 156.10M | 214.44M | 118.77M | 107.42M | 91.54M | 164.92M | 87.95M |
| Short-Term Debt | — | — | — | — | — | — | 0 | 91.59M | 91.50M | 105.59M | 105.48M | — |
| Total Current Liabilities | 502.91M | 499.16M | 1.10B | 921.42M | 919.95M | 605.59M | 731.68M | 699.49M | 688.49M | 608.71M | 653.66M | 450.74M |
| Long-Term Debt | 847.62M | 838.16M | 828.97M | 140.50M | — | — | 1.14B | 1.23B | 1.23B | 1.24B | 1.24B | 1.24B |
| Total Liabilities | 1.66B | 1.67B | 2.21B | 2.17B | 2.32B | 2.32B | 2.44B | 2.38B | 2.35B | 2.26B | 2.41B | 2.35B |
| Shareholders' Equity | 1.53B | 1.51B | 1.14B | 1.32B | 1.40B | 1.19B | 1.53B | 1.22B | 1.08B | 961.19M | 859.34M | 764.36M |
| Retained Earnings | -4.55B | -4.55B | -4.88B | -4.64B | -4.46B | -4.66B | -4.21B | -4.37B | -4.40B | -4.41B | -4.45B | -4.49B |
| Total Debt | 847.62M | 838.16M | 828.97M | 140.50M | — | — | 1.14B | 1.32B | 1.32B | 1.34B | 1.34B | 1.24B |
| Net Cash (Debt) | -59.13M | -184.97M | 110.68M | 710.49M | 800.14M | 522.76M | 217.67M | -120.77M | 142.65M | 45.91M | 332.77M | 496.79M |
| Shares Outstanding | 105.62M | 105.57M | 104.96M | 104.77M | 97.71M | 98.25M | 96.90M | 95.49M | 95.28M | 94.49M | 93.73M | 93.54M |
This table shows 12 quarterly periods of Sarepta Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SRPT's reporting calendar. What is a balance sheet?